Industry news that matters to you.  Learn more

Regeneron Launches New Human Genetics Initiative

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently announced that it has launched a new human genetics initiative via a new wholly owned subsidiary, the Regeneron Genetics Center LLC (RGC). The objective of the RGC is to expand the use of human genetics for defining disease targets and improving the drug development process. The RGC will pursue both large population-based efforts as well as family-based approaches.